<DOC>
	<DOCNO>NCT00643565</DOCNO>
	<brief_summary>This open-label two-arm study assess safety efficacy combination bevacizumab + standard chemotherapy standard chemotherapy alone active comparator childhood adolescent patient metastatic rhabdomyosarcoma non-rhabdomyosarcoma soft tissue sarcoma . Patients randomize receive bevacizumab + standard chemotherapy standard chemotherapy alone . Treatment consist 9 x 3-week cycle induction treatment ( standard chemotherapy without bevacizumab 7.5 mg/kg iv day 1 cycle ) follow 12 x 4-week cycle maintenance treatment ( standard chemotherapy without bevacizumab 5 mg/kg iv day 1 15 cycle ) . The anticipated time study treatment 1-2 year .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Combination With Standard Chemotherapy Children Adolescents With Sarcoma .</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>childhood adolescent patient age &gt; /=6 month 18 year age metastatic rhabdomyosarcoma nonrhabdomyosarcoma soft tissue sarcoma adequate bone marrow function adequate renal liver function adequate blood clot previous malignant tumor tumor invade major blood vessel prior systemic antitumor treatment</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>